Huntington's Disease Market
DelveInsight's "Huntington’s disease - Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Huntington’s disease, historical and forecasted epidemiology as well as the Huntington’s disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Huntington’s disease market report provides current treatment practices, emerging drugs, Huntington’s disease market share of the individual therapies, current and forecasted Huntington’s disease market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Huntington’s disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Huntington’s disease (HD) Understanding and Treatment Algorithm
The DelveInsight’s Huntington’s disease market report gives a thorough understanding of the disease. Huntington’s disease (HD) is a rare, incurable, genetic, progressive neurodegenerative disorder that causes brain cells, termed as neurons, to die in several areas of the brain, together with those that help control voluntary (intentional) movement. It is passed on (inherited) from a person’s parents and known to get worse over time, disturbing the patient’s physical movements, emotions, and cognitive abilities. Huntington’s disease is named after George Huntington, the physician who described it as hereditary chorea in 1872.
Huntington’s disease is caused by an error in the DNA commands that build our bodies and keep them running. DNA is made up of thousands of genes, and people with Huntington’s disease have a small fault in one gene, chromosome 4 – one of the 23 human chromosomes that carry a person’s entire genetic code. This defect is “dominant,” meaning that any person who inherits it from a parent with Huntington’s will develop the disease in the long run. The faulty gene codes the blueprint for a protein called huntingtin. This protein’s normal function is not yet known; however, it is called “huntingtin” because scientists acknowledged its defective form as the cause of Huntington’s disease. Over time, this defective huntingtin protein leads to brain changes that cause abnormal involuntary movements, a severe decline in thinking and reasoning skills, and irritability, depression, and other mood changes. Huntington’s disease symptoms can develop at any time, but they often first appear when people are in their 30s or 40s.
The only cause behind the occurrence of Huntington’s disease is a faulty gene that results in parts of the brain gradually becoming impaired over time. It is inherited as an autosomal dominant trait.
A person is generally only at risk of developing it if one of the parents has or had it. In dominant disorders, a single copy of the disease gene (received from either the mother or father) will be expressed “dominating” the other normal gene and resulting in the appearance of the disease. Both men and women can get it since the risk of transmitting the disorder from affected parent to offspring is 50% for each pregnancy regardless of the sex of the resulting child.
The progression of Huntington’s disease can be described in five stages/phases. For diagnosis specialized x-ray studies such as computerized tomography (CT) scanning, magnetic resonance imaging (MRI), or electroencephalography (EEG) may help confirm the diagnosis of Huntington’s disease. During CT scanning, a computer and x-rays are used to create a file showing cross-sectional images of the brain.
Treatment
Unfortunately, there is no cure for Huntington’s disease, and there are no treatments known to slow or reverse its process. No treatments can alter the course of Huntington’s disease. However, medications can lessen some symptoms of movement and psychiatric disorders. And multiple interventions can help a person adapt to changes in their abilities for a certain amount of time
It is important to note that medications used to treat patients with Huntington’s disease are targeted to specific symptoms. Medications will likely change throughout the disease, depending on overall treatment goals and the patient’s condition. In addition, drugs that treat some symptoms may result in side effects that worsen other symptoms. Treatment goals are regularly reviewed and updated by the doctors. The current goal of treatment is to slow down the course of the disease and help affected people function comfortably for as long as possible
Currently, the treatment strategies include the usage of many medications to treat specific symptoms such as medicines for depression, mood swings, and involuntary/abnormal movements and behaviors. Depression and suicide are more common among affected people, so caregivers should monitor for associated symptoms and seek help if necessary. It becomes crucial for caregivers to watch symptoms closely and seek medical help immediately when issues or questions come up. As symptoms of the disease worsen, affected people need more assistance, supervision, and care.
Medicines which are being used are, dopamine blocker, antidepressants, antipsychotics and mood-stabilizing drugs.
Huntington's Disease Epidemiology
The Huntington’s disease epidemiology section provides insights about historical and current Huntington’s disease patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
In the year 2021, the total prevalent cases of Huntington’s disease were 80,170 in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
The disease epidemiology covered in the report provides historical as well as forecasted Huntington’s disease epidemiology ,segmented as Total Prevalent cases of Huntington’s disease, Total Diagnosed Prevalent cases of Huntington’s disease, Total Chorea associated cases of Huntington’s disease, Total Diagnosed Prevalent cases of Huntington’s disease by age group, Total Diagnosed Prevalent cases of Huntington's disease by Clinical Stage and Total Treated cases of Huntington’s disease in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Huntington’s disease (HD) Epidemiology
The epidemiology segment also provides the Huntington’s disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Huntington’s disease (HD) Drug Chapters
The drug chapter segment of the Huntington’s disease report encloses the detailed analysis of Huntington’s disease marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Huntington’s disease clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.
Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Huntington’s disease treatment.
Huntington’s disease (HD) Market Outlook
The Huntington’s disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Huntington’s disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, barriers, and demand for better technology.
This segment gives a thorough detail of Huntington’s disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Huntington’s disease market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
The Huntington’s disease market size in the 7MM is expected to change during the study period 2019–2032. The therapeutic market of Huntington’s disease in the seven major markets is expected to increase during the study period (2019–2032). In 2021, the total market size of Huntington’s disease was USD 198.66 million which is expected to rise during the study period (2019–2032).
The United States Market Outlook
The total market size of Huntington’s disease in the United States accounted for USD 187.06 million in 2021 which is expected to rise during the study period (2019–2032).
EU-5 Countries: Market Outlook
In EU5, the total market size of Huntington’s disease was USD 11.03 million in 2021, which is expected to rise during the study period (2019–2032).
Japan Market Outlook
In Japan, the total market size of Huntington’s disease was USD 0.57 million in 2021, which is expected to rise during the study period (2019–2032).
Huntington’s disease (HD) Uptake
This section focuses on the rate of uptake of the potential Huntington's Disease drugs recently launched in the Huntington’s disease market or expected to get launched in the market during the study period 2019-2032. The analysis covers Huntington’s disease market uptake by drugs; patient uptake by therapies; and sales of each drug.
This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allows the comparison of the drugs based on market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Huntington’s disease (HD) Pipeline Development Activities
The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Huntington’s disease key players involved in developing targeted therapeutics.
Pipeline Development Activities
The report covers detailed information on collaborations, acquisition, and merger, licensing patent details, and other information for Huntington’s disease emerging therapies.
Reimbursement Scenario in Huntington’s disease (HD)
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current market trends, we take KOLs and SMEs ' opinions working in the Huntington’s disease domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Huntington’s disease market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitively and Market Intelligence analysis of the Huntington’s disease Market by using various Competitive Intelligence tools that include - SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Huntington’s disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis, and currently available therapies
- Comprehensive insight has been provided into the Huntington’s disease epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Huntington’s disease are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Huntington’s disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Huntington’s disease market.
Report Highlights
- In the coming years, the Huntington’s disease market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics are working to assess challenges and seek opportunities that could influence Huntington’s disease R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- Major players are involved in developing therapies for Huntington’s disease. The launch of emerging therapies will significantly impact the Huntington’s disease market.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Huntington’s disease.
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Huntington’s disease (HD) Report Insights
- Patient Population
- Therapeutic Approaches
- Huntington’s disease Pipeline Analysis
- Huntington’s disease Market Size and Trends
- Market Opportunities
- Impact of upcoming Therapies
Huntington’s disease (HD) Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Huntington’s disease Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Huntington’s disease (HD) Report Assessment
- Current Treatment Practices
- Unmet Needs
- Pipeline Product Profiles
- Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Huntington’s disease drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Huntington’s disease total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings of the market across 7MM and which country will have the largest Huntington’s disease market size during the forecast period (2019-2032)?
- At what CAGR, the Huntington’s disease market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Huntington’s disease market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Huntington’s disease market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needs affect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of Huntington’s disease?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Huntington’s disease patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Huntington’s disease in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about Huntington’s disease?
- Out of all 7MM countries, which country would have the highest prevalent population of Huntington’s disease during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:
- What are the current options for the Huntington’s disease treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Huntington’s disease in the USA, Europe, and Japan?
- What are the Huntington’s disease marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
- How many companies are developing therapies for the treatment of Huntington’s disease?
- How many therapies are in-development by each company for Huntington’s disease treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Huntington’s disease treatment?
- What are the key collaborations (Industry - Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Huntington’s disease therapies?
- What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Huntington’s disease and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Huntington’s disease?
- What are the global historical and forecasted markets of Huntington’s disease?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Huntington’s disease market
- To understand the future market competition in the Huntington’s disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Huntington’s disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the Huntington’s disease market
- To understand the future market competition in the Huntington’s disease market
